Cargando…

Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients

BACKGROUND: Venovenous extracorporeal membrane oxygenation (VV-ECMO) is associated with a significant morbidity. There is the need to investigate long-term cognitive outcome among ARDS survivors treated with VV-ECMO. We aimed to compare the prevalence of long-term cognitive dysfunction and neuropsyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sylvestre, Aude, Adda, Mélanie, Maltese, François, Lannelongue, Ariane, Daviet, Florence, Parzy, Gabriel, Coiffard, Benjamin, Roch, Antoine, Loundou, Anderson, Baumstarck, Karine, Papazian, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635548/
https://www.ncbi.nlm.nih.gov/pubmed/31312911
http://dx.doi.org/10.1186/s13613-019-0556-1
_version_ 1783435903921815552
author Sylvestre, Aude
Adda, Mélanie
Maltese, François
Lannelongue, Ariane
Daviet, Florence
Parzy, Gabriel
Coiffard, Benjamin
Roch, Antoine
Loundou, Anderson
Baumstarck, Karine
Papazian, Laurent
author_facet Sylvestre, Aude
Adda, Mélanie
Maltese, François
Lannelongue, Ariane
Daviet, Florence
Parzy, Gabriel
Coiffard, Benjamin
Roch, Antoine
Loundou, Anderson
Baumstarck, Karine
Papazian, Laurent
author_sort Sylvestre, Aude
collection PubMed
description BACKGROUND: Venovenous extracorporeal membrane oxygenation (VV-ECMO) is associated with a significant morbidity. There is the need to investigate long-term cognitive outcome among ARDS survivors treated with VV-ECMO. We aimed to compare the prevalence of long-term cognitive dysfunction and neuropsychological impairment using a highly specific test in severe ARDS survivors treated or not treated with VV-ECMO. METHODS: Severe ARDS survivors treated between 2011 and 2017 in an ECMO Regional Referral Center were prospectively evaluated 2 years after their ICU discharge. Patients underwent an in-person interview and examination. The primary outcome was cognitive function, assessed by the Wechsler Adult Intelligence Scale 4th edition (WAIS-IV). Secondary outcomes included anxiety, depression, post-traumatic stress disorder (PTSD) and quality-of-life. RESULTS: We investigated 40 consecutive patients surviving from severe ARDS treated (N = 22) or not (N = 18) with VV-ECMO at a median [interquartile range] of 20 [17–22] and 22 [18–23] months after ICU discharge, respectively. Regarding the main outcome, cognitive function was below normal ranges in 12 (55%) ECMO patients and 10 (56%) non-ECMO patients (p = 0.95). Eight (36%) ECMO patients had moderate-to-severe depressive symptoms as compared with 7 (39%) non-ECMO patients (p = 0.87). Twelve (55%) ECMO patients and eight (44%) non-ECMO patients had moderate-to-severe anxiety symptoms (p = 0.53). Seven (33%) ECMO patients and eight (44%) non-ECMO patients presented a PTSD (p = 0.48). Health-related quality of life did not differ between the two groups. CONCLUSIONS: Using the WAIS-IV, VV-ECMO treatment does not appear to worsen long-term cognitive and neuropsychological outcomes in severe ARDS patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13613-019-0556-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6635548
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-66355482019-08-01 Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients Sylvestre, Aude Adda, Mélanie Maltese, François Lannelongue, Ariane Daviet, Florence Parzy, Gabriel Coiffard, Benjamin Roch, Antoine Loundou, Anderson Baumstarck, Karine Papazian, Laurent Ann Intensive Care Research BACKGROUND: Venovenous extracorporeal membrane oxygenation (VV-ECMO) is associated with a significant morbidity. There is the need to investigate long-term cognitive outcome among ARDS survivors treated with VV-ECMO. We aimed to compare the prevalence of long-term cognitive dysfunction and neuropsychological impairment using a highly specific test in severe ARDS survivors treated or not treated with VV-ECMO. METHODS: Severe ARDS survivors treated between 2011 and 2017 in an ECMO Regional Referral Center were prospectively evaluated 2 years after their ICU discharge. Patients underwent an in-person interview and examination. The primary outcome was cognitive function, assessed by the Wechsler Adult Intelligence Scale 4th edition (WAIS-IV). Secondary outcomes included anxiety, depression, post-traumatic stress disorder (PTSD) and quality-of-life. RESULTS: We investigated 40 consecutive patients surviving from severe ARDS treated (N = 22) or not (N = 18) with VV-ECMO at a median [interquartile range] of 20 [17–22] and 22 [18–23] months after ICU discharge, respectively. Regarding the main outcome, cognitive function was below normal ranges in 12 (55%) ECMO patients and 10 (56%) non-ECMO patients (p = 0.95). Eight (36%) ECMO patients had moderate-to-severe depressive symptoms as compared with 7 (39%) non-ECMO patients (p = 0.87). Twelve (55%) ECMO patients and eight (44%) non-ECMO patients had moderate-to-severe anxiety symptoms (p = 0.53). Seven (33%) ECMO patients and eight (44%) non-ECMO patients presented a PTSD (p = 0.48). Health-related quality of life did not differ between the two groups. CONCLUSIONS: Using the WAIS-IV, VV-ECMO treatment does not appear to worsen long-term cognitive and neuropsychological outcomes in severe ARDS patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13613-019-0556-1) contains supplementary material, which is available to authorized users. Springer International Publishing 2019-07-16 /pmc/articles/PMC6635548/ /pubmed/31312911 http://dx.doi.org/10.1186/s13613-019-0556-1 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Sylvestre, Aude
Adda, Mélanie
Maltese, François
Lannelongue, Ariane
Daviet, Florence
Parzy, Gabriel
Coiffard, Benjamin
Roch, Antoine
Loundou, Anderson
Baumstarck, Karine
Papazian, Laurent
Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients
title Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients
title_full Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients
title_fullStr Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients
title_full_unstemmed Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients
title_short Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients
title_sort long-term neurocognitive outcome is not worsened by of the use of venovenous ecmo in severe ards patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635548/
https://www.ncbi.nlm.nih.gov/pubmed/31312911
http://dx.doi.org/10.1186/s13613-019-0556-1
work_keys_str_mv AT sylvestreaude longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients
AT addamelanie longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients
AT maltesefrancois longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients
AT lannelongueariane longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients
AT davietflorence longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients
AT parzygabriel longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients
AT coiffardbenjamin longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients
AT rochantoine longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients
AT loundouanderson longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients
AT baumstarckkarine longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients
AT papazianlaurent longtermneurocognitiveoutcomeisnotworsenedbyoftheuseofvenovenousecmoinsevereardspatients